ID   KIT_HUMAN               Reviewed;         976 AA.
AC   P10721; B5A956; D5LXN2; D5M931; F5H8F8; Q6IQ28; Q99662; Q9UM99;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1989, sequence version 1.
DT   10-MAY-2017, entry version 209.
DE   RecName: Full=Mast/stem cell growth factor receptor Kit;
DE            Short=SCFR;
DE            EC=2.7.10.1;
DE   AltName: Full=Piebald trait protein;
DE            Short=PBT;
DE   AltName: Full=Proto-oncogene c-Kit;
DE   AltName: Full=Tyrosine-protein kinase Kit;
DE   AltName: Full=p145 c-kit;
DE   AltName: Full=v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog;
DE   AltName: CD_antigen=CD117;
DE   Flags: Precursor;
GN   Name=KIT; Synonyms=SCFR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), CATALYTIC ACTIVITY,
RP   AUTOPHOSPHORYLATION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Fetal brain, and Term placenta;
RX   PubMed=2448137;
RA   Yarden Y., Kuang W.-J., Yang-Feng T., Coussens L., Munemitsu S.,
RA   Dull T.J., Chen E., Schlessinger J., Francke U., Ullrich A.;
RT   "Human proto-oncogene c-kit: a new cell surface receptor tyrosine
RT   kinase for an unidentified ligand.";
RL   EMBO J. 6:3341-3351(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING (ISOFORMS
RP   1 AND 2).
RX   PubMed=1279499;
RA   Giebel L.B., Strunk K.M., Holmes S.A., Spritz R.A.;
RT   "Organization and nucleotide sequence of the human KIT (mast/stem cell
RT   growth factor receptor) proto-oncogene.";
RL   Oncogene 7:2207-2217(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9027509; DOI=10.1006/geno.1996.4482;
RA   Andre C., Hampe A., Lachaume P., Martin E., Wang X.P., Manus V.,
RA   Hu W.X., Galibert F.;
RT   "Sequence analysis of two genomic regions containing the KIT and the
RT   FMS receptor tyrosine kinase genes.";
RL   Genomics 39:216-226(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RX   PubMed=18593464; DOI=10.1186/ar2447;
RA   Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D.,
RA   Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.;
RT   "Novel splice variants derived from the receptor tyrosine kinase
RT   superfamily are potential therapeutics for rheumatoid arthritis.";
RL   Arthritis Res. Ther. 10:R73-R73(2008).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), SUBCELLULAR LOCATION, AND
RP   INDUCTION.
RX   PubMed=20658618; DOI=10.1002/pbc.22603;
RA   Neumann I., Foell J.L., Bremer M., Volkmer I., Korholz D., Burdach S.,
RA   Staege M.S.;
RT   "Retinoic acid enhances sensitivity of neuroblastoma cells for
RT   imatinib mesylate.";
RL   Pediatr. Blood Cancer 55:464-470(2010).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Staege M.S., Neumann I., Volkmer I.;
RT   "Sequence of KIT mRNA from all-trans retinoic acid treated
RT   neuroblastoma cell lines.";
RL   Submitted (MAR-2010) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-22.
RX   PubMed=7506248; DOI=10.1111/j.1349-7006.1993.tb02813.x;
RA   Yamamoto K., Tojo A., Aoki N., Shibuya M.;
RT   "Characterization of the promoter region of the human c-kit proto-
RT   oncogene.";
RL   Jpn. J. Cancer Res. 84:1136-1144(1993).
RN   [11]
RP   FUNCTION IN PHOSPHORYLATION OF PIK3R1; RAF1 AND MAPK1, INTERACTION
RP   WITH GRB2; PIK3R1 AND PIK3 CATALYTIC SUBUNIT, ENZYME REGULATION, AND
RP   PHOSPHORYLATION.
RX   PubMed=7520444;
RA   Blume-Jensen P., Ronnstrand L., Gout I., Waterfield M.D., Heldin C.H.;
RT   "Modulation of Kit/stem cell factor receptor-induced signaling by
RT   protein kinase C.";
RL   J. Biol. Chem. 269:21793-21802(1994).
RN   [12]
RP   PHOSPHORYLATION AT SER-741; SER-746; SER-821 AND SER-959, ENZYME
RP   REGULATION, PARTIAL PROTEIN SEQUENCE, AND MUTAGENESIS OF SER-741 AND
RP   SER-746.
RX   PubMed=7539802; DOI=10.1074/jbc.270.23.14192;
RA   Blume-Jensen P., Wernstedt C., Heldin C.H., Ronnstrand L.;
RT   "Identification of the major phosphorylation sites for protein kinase
RT   C in kit/stem cell factor receptor in vitro and in intact cells.";
RL   J. Biol. Chem. 270:14192-14200(1995).
RN   [13]
RP   INTERACTION WITH PIK3R1; MATK/CHK; FYN AND SHC1, AND PHOSPHORYLATION
RP   AT TYR-568; TYR-570 AND TYR-721.
RX   PubMed=9038210; DOI=10.1074/jbc.272.9.5915;
RA   Price D.J., Rivnay B., Fu Y., Jiang S., Avraham S., Avraham H.;
RT   "Direct association of Csk homologous kinase (CHK) with the
RT   diphosphorylated site Tyr568/570 of the activated c-KIT in
RT   megakaryocytes.";
RL   J. Biol. Chem. 272:5915-5920(1997).
RN   [14]
RP   INTERACTION WITH LYN.
RX   PubMed=9341198; DOI=10.1074/jbc.272.43.27450;
RA   Linnekin D., DeBerry C.S., Mou S.;
RT   "Lyn associates with the juxtamembrane region of c-Kit and is
RT   activated by stem cell factor in hematopoietic cell lines and normal
RT   progenitor cells.";
RL   J. Biol. Chem. 272:27450-27455(1997).
RN   [15]
RP   INTERACTION WITH PTPN6, AUTOPHOSPHORYLATION, AND FUNCTION IN
RP   PHOSPHORYLATION OF PTPN6.
RX   PubMed=9528781; DOI=10.1128/MCB.18.4.2089;
RA   Kozlowski M., Larose L., Lee F., Le D.M., Rottapel R.,
RA   Siminovitch K.A.;
RT   "SHP-1 binds and negatively modulates the c-Kit receptor by
RT   interaction with tyrosine 569 in the c-Kit juxtamembrane domain.";
RL   Mol. Cell. Biol. 18:2089-2099(1998).
RN   [16]
RP   INTERACTION WITH GRB2 AND GRB7, PARTIAL PROTEIN SEQUENCE,
RP   AUTOPHOSPHORYLATION, AND PHOSPHORYLATION AT TYR-703 AND TYR-936.
RX   PubMed=10377264; DOI=10.1042/bj3410211;
RA   Thommes K., Lennartsson J., Carlberg M., Ronnstrand L.;
RT   "Identification of Tyr-703 and Tyr-936 as the primary association
RT   sites for Grb2 and Grb7 in the c-Kit/stem cell factor receptor.";
RL   Biochem. J. 341:211-216(1999).
RN   [17]
RP   INTERACTION WITH PTPRU, AND FUNCTION IN PHOSPHORYLATION OF PTPRU.
RX   PubMed=10397721;
RA   Taniguchi Y., London R., Schinkmann K., Jiang S., Avraham H.;
RT   "The receptor protein tyrosine phosphatase, PTP-RO, is upregulated
RT   during megakaryocyte differentiation and is associated with the c-Kit
RT   receptor.";
RL   Blood 94:539-549(1999).
RN   [18]
RP   INTERACTION WITH MPDZ, CHARACTERIZATION OF VARIANT VAL-816, AND
RP   MUTAGENESIS OF LYS-623.
RX   PubMed=11018522; DOI=10.1016/S0014-5793(00)02036-6;
RA   Mancini A., Koch A., Stefan M., Niemann H., Tamura T.;
RT   "The direct association of the multiple PDZ domain containing proteins
RT   (MUPP-1) with the human c-Kit C-terminus is regulated by tyrosine
RT   kinase activity.";
RL   FEBS Lett. 482:54-58(2000).
RN   [19]
RP   INTERACTION WITH LYN; TEC AND DOK1.
RX   PubMed=11825908; DOI=10.1074/jbc.M200277200;
RA   Liang X., Wisniewski D., Strife A., Shivakrupa R., Clarkson B.,
RA   Resh M.D.;
RT   "Phosphatidylinositol 3-kinase and Src family kinases are required for
RT   phosphorylation and membrane recruitment of Dok-1 in c-Kit
RT   signaling.";
RL   J. Biol. Chem. 277:13732-13738(2002).
RN   [20]
RP   INTERACTION WITH SH2B2/APS, FUNCTION IN PHOSPHORYLATION OF SH2B2/APS,
RP   AND MUTAGENESIS OF ILE-571 AND LEU-939.
RX   PubMed=12444928; DOI=10.1042/BJ20020716;
RA   Wollberg P., Lennartsson J., Gottfridsson E., Yoshimura A.,
RA   Ronnstrand L.;
RT   "The adapter protein APS associates with the multifunctional docking
RT   sites Tyr-568 and Tyr-936 in c-Kit.";
RL   Biochem. J. 370:1033-1038(2003).
RN   [21]
RP   PHOSPHORYLATION AT SER-891 AND TYR-900, PARTIAL PROTEIN SEQUENCE,
RP   INTERACTION WITH CRK AND PIK3R1, FUNCTION IN PHOSPHORYLATION OF CRK;
RP   AKT1 AND MAP KINASES, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=12878163; DOI=10.1016/S0014-4827(03)00206-4;
RA   Lennartsson J., Wernstedt C., Engstrom U., Hellman U., Ronnstrand L.;
RT   "Identification of Tyr900 in the kinase domain of c-Kit as a Src-
RT   dependent phosphorylation site mediating interaction with c-Crk.";
RL   Exp. Cell Res. 288:110-118(2003).
RN   [22]
RP   FUNCTION, AND ALTERNATIVE SPLICING.
RX   PubMed=12511554; DOI=10.1074/jbc.M211726200;
RA   Voytyuk O., Lennartsson J., Mogi A., Caruana G., Courtneidge S.,
RA   Ashman L.K., Ronnstrand L.;
RT   "Src family kinases are involved in the differential signaling from
RT   two splice forms of c-Kit.";
RL   J. Biol. Chem. 278:9159-9166(2003).
RN   [23]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-130.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [24]
RP   INTERACTION WITH FES/FPS, AND CHARACTERIZATION OF VARIANT VAL-816.
RX   PubMed=17595334; DOI=10.1182/blood-2007-02-076471;
RA   Voisset E., Lopez S., Dubreuil P., De Sepulveda P.;
RT   "The tyrosine kinase FES is an essential effector of KITD816V
RT   proliferation signal.";
RL   Blood 110:2593-2599(2007).
RN   [25]
RP   INTERACTION WITH GRB2 AND CBL, UBIQUITINATION, AND FUNCTION IN
RP   PHOSPHORYLATION OF CBL.
RX   PubMed=17904548; DOI=10.1016/j.yexcr.2007.08.021;
RA   Sun J., Pedersen M., Bengtsson S., Ronnstrand L.;
RT   "Grb2 mediates negative regulation of stem cell factor receptor/c-Kit
RT   signaling by recruitment of Cbl.";
RL   Exp. Cell Res. 313:3935-3942(2007).
RN   [26]
RP   FUNCTION IN ACTIVATION OF SIGNALING PATHWAYS AND CELL SURVIVAL,
RP   FUNCTION IN PHOSPHORYLATION OF CBL, PHOSPHORYLATION AT TYR-568;
RP   TYR-703; TYR-721 AND TYR-936, UBIQUITINATION, SUBCELLULAR LOCATION,
RP   AND CHARACTERIZATION OF VARIANT VAL-816.
RX   PubMed=19265199; DOI=10.1074/jbc.M808058200;
RA   Sun J., Pedersen M., Ronnstrand L.;
RT   "The D816V mutation of c-Kit circumvents a requirement for Src family
RT   kinases in c-Kit signal transduction.";
RL   J. Biol. Chem. 284:11039-11047(2009).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-959, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [28]
RP   SUBCELLULAR LOCATION, ALTERNATIVE SPLICING, AND TISSUE SPECIFICITY.
RX   PubMed=20601678; DOI=10.1093/humrep/deq168;
RA   Muciaccia B., Sette C., Paronetto M.P., Barchi M., Pensini S.,
RA   D'Agostino A., Gandini L., Geremia R., Stefanini M., Rossi P.;
RT   "Expression of a truncated form of KIT tyrosine kinase in human
RT   spermatozoa correlates with sperm DNA integrity.";
RL   Hum. Reprod. 25:2188-2202(2010).
RN   [29]
RP   PHOSPHORYLATION AT TYR-547; TYR-553; TYR-703; TYR-721; TYR-730;
RP   TYR-823 AND TYR-900, IDENTIFICATION BY MASS SPECTROMETRY, MUTAGENESIS
RP   OF TYR-823, AND CHARACTERIZATION OF VARIANT HIS-816.
RX   PubMed=20147452; DOI=10.1093/jb/mvq015;
RA   DiNitto J.P., Deshmukh G.D., Zhang Y., Jacques S.L., Coli R.,
RA   Worrall J.W., Diehl W., English J.M., Wu J.C.;
RT   "Function of activation loop tyrosine phosphorylation in the mechanism
RT   of c-Kit auto-activation and its implication in sunitinib
RT   resistance.";
RL   J. Biochem. 147:601-609(2010).
RN   [30]
RP   FUNCTION, CATALYTIC ACTIVITY, ENZYME REGULATION, AUTOPHOSPHORYLATION,
RP   SUBUNIT, AND CHARACTERIZATION OF VARIANT VAL-816.
RX   PubMed=21640708; DOI=10.1016/j.bbrc.2011.05.111;
RA   Kim S.Y., Kang J.J., Lee H.H., Kang J.J., Kim B., Kim C.G., Park T.K.,
RA   Kang H.;
RT   "Mechanism of activation of human c-KIT kinase by internal tandem
RT   duplications of the juxtamembrane domain and point mutations at
RT   aspartic acid 816.";
RL   Biochem. Biophys. Res. Commun. 410:224-228(2011).
RN   [31]
RP   FUNCTION IN ACTIVATION AND PHOSPHORYLATION OF STAT1; STAT3; STAT5A AND
RP   STAT5B.
RX   PubMed=21135090; DOI=10.1074/jbc.M110.182642;
RA   Chaix A., Lopez S., Voisset E., Gros L., Dubreuil P., De Sepulveda P.;
RT   "Mechanisms of STAT protein activation by oncogenic KIT mutants in
RT   neoplastic mast cells.";
RL   J. Biol. Chem. 286:5956-5966(2011).
RN   [32]
RP   REVIEW.
RX   PubMed=15526160; DOI=10.1007/s00018-004-4189-6;
RA   Ronnstrand L.;
RT   "Signal transduction via the stem cell factor receptor/c-Kit.";
RL   Cell. Mol. Life Sci. 61:2535-2548(2004).
RN   [33]
RP   REVIEW ON KIT SIGNALING.
RX   PubMed=16129412; DOI=10.1016/j.bbrc.2005.08.055;
RA   Roskoski R. Jr.;
RT   "Signaling by Kit protein-tyrosine kinase--the stem cell factor
RT   receptor.";
RL   Biochem. Biophys. Res. Commun. 337:1-13(2005).
RN   [34]
RP   REVIEW.
RX   PubMed=15625120; DOI=10.1634/stemcells.2004-0117;
RA   Lennartsson J., Jelacic T., Linnekin D., Shivakrupa R.;
RT   "Normal and oncogenic forms of the receptor tyrosine kinase kit.";
RL   Stem Cells 23:16-43(2005).
RN   [35]
RP   REVIEW.
RX   PubMed=18381929; DOI=10.1158/1078-0432.CCR-07-5134;
RA   Kent D., Copley M., Benz C., Dykstra B., Bowie M., Eaves C.;
RT   "Regulation of hematopoietic stem cells by the steel factor/KIT
RT   signaling pathway.";
RL   Clin. Cancer Res. 14:1926-1930(2008).
RN   [36]
RP   REVIEW.
RX   PubMed=21057534; DOI=10.1038/onc.2010.494;
RA   Pittoni P., Piconese S., Tripodo C., Colombo M.P.;
RT   "Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the
RT   primary off-target of tyrosine kinase inhibitors.";
RL   Oncogene 30:757-769(2011).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 549-931 IN COMPLEX WITH ADP
RP   AND MAGNESIUM IONS, SUBUNIT, PHOSPHORYLATION AT TYR-568 AND TYR-570,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=12824176; DOI=10.1074/jbc.C300186200;
RA   Mol C.D., Lim K.B., Sridhar V., Zou H., Chien E.Y., Sang B.C.,
RA   Nowakowski J., Kassel D.B., Cronin C.N., McRee D.E.;
RT   "Structure of a c-kit product complex reveals the basis for kinase
RT   transactivation.";
RL   J. Biol. Chem. 278:31461-31464(2003).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 565-935 IN COMPLEXES WITH
RP   INHIBITOR IMATINIB AND PHOSPHATE, AND ENZYME REGULATION.
RX   PubMed=15123710; DOI=10.1074/jbc.M403319200;
RA   Mol C.D., Dougan D.R., Schneider T.R., Skene R.J., Kraus M.L.,
RA   Scheibe D.N., Snell G.P., Zou H., Sang B.C., Wilson K.P.;
RT   "Structural basis for the autoinhibition and STI-571 inhibition of c-
RT   Kit tyrosine kinase.";
RL   J. Biol. Chem. 279:31655-31663(2004).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 1-519 IN COMPLEX WITH
RP   KITLG/SCF, INTERACTION WITH KITLG/SCF, SUBUNIT, DISULFIDE BONDS,
RP   CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, MUTAGENESIS OF ARG-381 AND
RP   GLU-386, AND GLYCOSYLATION AT ASN-130; ASN-283; ASN-293; ASN-300;
RP   ASN-320; ASN-352 AND ASN-367.
RX   PubMed=17662946; DOI=10.1016/j.cell.2007.05.055;
RA   Yuzawa S., Opatowsky Y., Zhang Z., Mandiyan V., Lax I.,
RA   Schlessinger J.;
RT   "Structural basis for activation of the receptor tyrosine kinase KIT
RT   by stem cell factor.";
RL   Cell 130:323-334(2007).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 544-935 IN COMPLEX WITH
RP   SUNITINIB, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, CHARACTERIZATION
RP   OF VARIANTS HIS-816 AND VAL-816, AND ENZYME REGULATION.
RX   PubMed=19164557; DOI=10.1073/pnas.0812413106;
RA   Gajiwala K.S., Wu J.C., Christensen J., Deshmukh G.D., Diehl W.,
RA   DiNitto J.P., English J.M., Greig M.J., He Y.A., Jacques S.L.,
RA   Lunney E.A., McTigue M., Molina D., Quenzer T., Wells P.A., Yu X.,
RA   Zhang Y., Zou A., Emmett M.R., Marshall A.G., Zhang H.M.,
RA   Demetri G.D.;
RT   "KIT kinase mutants show unique mechanisms of drug resistance to
RT   imatinib and sunitinib in gastrointestinal stromal tumor patients.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:1542-1547(2009).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (1.45 ANGSTROMS) OF 564-574 IN COMPLEX WITH
RP   SOCS6, AND PHOSPHORYLATION AT TYR-568.
RX   PubMed=21030588; DOI=10.1074/jbc.M110.173526;
RA   Zadjali F., Pike A.C., Vesterlund M., Sun J., Wu C., Li S.S.,
RA   Ronnstrand L., Knapp S., Bullock A.N., Flores-Morales A.;
RT   "Structural basis for c-KIT inhibition by the suppressor of cytokine
RT   signaling 6 (SOCS6) ubiquitin ligase.";
RL   J. Biol. Chem. 286:480-490(2011).
RN   [42]
RP   VARIANT PBT LYS-583.
RX   PubMed=1376329; DOI=10.1172/JCI115772;
RA   Fleischman R.A.;
RT   "Human piebald trait resulting from a dominant negative mutant allele
RT   of the c-kit membrane receptor gene.";
RL   J. Clin. Invest. 89:1713-1717(1992).
RN   [43]
RP   VARIANT PBT LEU-584.
RX   PubMed=1370874;
RA   Spritz R.A., Giebel L.B., Holmes S.A.;
RT   "Dominant negative and loss of function mutations of the c-kit
RT   (mast/stem cell growth factor receptor) proto-oncogene in human
RT   piebaldism.";
RL   Am. J. Hum. Genet. 50:261-269(1992).
RN   [44]
RP   VARIANT PBT ARG-664.
RX   PubMed=1717985; DOI=10.1073/pnas.88.19.8696;
RA   Giebel L.B., Spritz R.A.;
RT   "Mutation of the KIT (mast/stem cell growth factor receptor)
RT   protooncogene in human piebaldism.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:8696-8699(1991).
RN   [45]
RP   VARIANT MAST CELL LEUKEMIA VAL-816.
RX   PubMed=7691885; DOI=10.1172/JCI116761;
RA   Furitsu T., Tsujimura T., Tono T., Ikeda H., Kitayama H.,
RA   Koshimizu U., Sugahara H., Butterfield J.H., Ashman L.K., Kanayama Y.,
RA   Matsuzawa Y., Kitamura Y., Kanakura Y.;
RT   "Identification of mutations in the coding sequence of the proto-
RT   oncogene c-kit in a human mast cell leukemia cell line causing ligand-
RT   independent activation of c-kit product.";
RL   J. Clin. Invest. 92:1736-1744(1993).
RN   [46]
RP   VARIANTS PBT GLY-791 AND VAL-812.
RX   PubMed=7687267; DOI=10.1111/1523-1747.ep12358440;
RA   Spritz R.A., Holmes S.A., Itin P., Kuester W.;
RT   "Novel mutations of the KIT (mast/stem cell growth factor receptor)
RT   proto-oncogene in human piebaldism.";
RL   J. Invest. Dermatol. 101:22-25(1993).
RN   [47]
RP   VARIANT PBT 893-GLU--PRO-896 DEL.
RX   PubMed=8680409; DOI=10.1002/humu.1380060409;
RA   Riva P., Milani N., Gandolfi P., Larizza L.;
RT   "A 12-bp deletion (7818del12) in the c-kit protooncogene in a large
RT   Italian kindred with piebaldism.";
RL   Hum. Mutat. 6:343-345(1995).
RN   [48]
RP   VARIANT MAST CELL DISEASE GLY-820.
RX   PubMed=9029028; DOI=10.1046/j.1365-2141.1997.d01-2042.x;
RA   Pignon J.-M., Giraudier S., Duquesnoy P., Jouault H., Imbert M.,
RA   Vainchenker W., Vernant J.-P., Tulliez M.;
RT   "A new c-kit mutation in a case of aggressive mast cell disease.";
RL   Br. J. Haematol. 96:374-376(1997).
RN   [49]
RP   VARIANT PBT GLY-796.
RX   PubMed=9450866;
RX   DOI=10.1002/(SICI)1096-8628(19980106)75:1<101::AID-AJMG20>3.0.CO;2-P;
RA   Spritz R.A., Beighton P.;
RT   "Piebaldism with deafness: molecular evidence for an expanded
RT   syndrome.";
RL   Am. J. Med. Genet. 75:101-103(1998).
RN   [50]
RP   VARIANT ACUTE MYELOID LEUKEMIA TYR-816.
RX   PubMed=9657776;
RA   Beghini A., Larizza L., Cairoli R., Morra E.;
RT   "c-kit activating mutations and mast cell proliferation in human
RT   leukemia.";
RL   Blood 92:701-702(1998).
RN   [51]
RP   VARIANT PBT PRO-847.
RX   PubMed=9699740; DOI=10.1046/j.1523-1747.1998.00269.x;
RA   Nomura K., Hatayama I., Narita T., Kaneko T., Shiraishi M.;
RT   "A novel KIT gene missense mutation in a Japanese family with
RT   piebaldism.";
RL   J. Invest. Dermatol. 111:337-338(1998).
RN   [52]
RP   VARIANT GIST VAL-559 DEL.
RX   PubMed=9697690; DOI=10.1038/1209;
RA   Nishida T., Hirota S., Taniguchi M., Hashimoto K., Isozaki K.,
RA   Nakamura H., Kanakura Y., Tanaka T., Takabayashi A., Matsuda H.,
RA   Kitamura Y.;
RT   "Familial gastrointestinal stromal tumours with germline mutation of
RT   the KIT gene.";
RL   Nat. Genet. 19:323-324(1998).
RN   [53]
RP   VARIANTS GIST ILE-550; 550-LYS--LYS-558 DEL; 551-PRO--VAL-555 DEL;
RP   ASP-559 AND 559-VAL-VAL-560 DEL.
RX   PubMed=9438854; DOI=10.1126/science.279.5350.577;
RA   Hirota S., Isozaki K., Moriyama Y., Hashimoto K., Nishida T.,
RA   Ishiguro S., Kawano K., Hanada M., Kurata A., Takeda M.,
RA   Muhammad Tunio G., Matsuzawa Y., Kanakura Y., Shinomura Y.,
RA   Kitamura Y.;
RT   "Gain-of-function mutations of c-kit in human gastrointestinal stromal
RT   tumors.";
RL   Science 279:577-580(1998).
RN   [54]
RP   VARIANT HIS-816, AND CHARACTERIZATION OF VARIANT HIS-816.
RX   PubMed=10362788; DOI=10.1016/S0002-9440(10)65419-3;
RA   Tian Q., Frierson H.F. Jr., Krystal G.W., Moskaluk C.A.;
RT   "Activating c-kit gene mutations in human germ cell tumors.";
RL   Am. J. Pathol. 154:1643-1647(1999).
RN   [55]
RP   VARIANTS MASTOCYTOSIS VAL-816; PHE-816; TYR-816 AND LYS-839, AND
RP   CHARACTERIZATION OF VARIANTS MASTOCYTOSIS VAL-816; PHE-816; TYR-816
RP   AND LYS-839.
RX   PubMed=9990072; DOI=10.1073/pnas.96.4.1609;
RA   Longley B.J. Jr., Metcalfe D.D., Tharp M., Wang X., Tyrrell L.,
RA   Lu S.-Z., Heitjan D., Ma Y.;
RT   "Activating and dominant inactivating c-KIT catalytic domain mutations
RT   in distinct clinical forms of human mastocytosis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:1609-1614(1999).
RN   [56]
RP   VARIANTS PBT CYS-584; ARG-601 AND PRO-656.
RX   PubMed=11074500;
RX   DOI=10.1002/1096-8628(20001106)95:1<79::AID-AJMG16>3.0.CO;2-4;
RA   Syrris P., Malik N.M., Murday V.A., Patton M.A., Carter N.D.,
RA   Hughes H.E., Metcalfe K.;
RT   "Three novel mutations of the proto-oncogene KIT cause human
RT   piebaldism.";
RL   Am. J. Med. Genet. 95:79-81(2000).
RN   [57]
RP   VARIANT GIST ALA-559.
RX   PubMed=11505412;
RX   DOI=10.1002/1097-0142(20010801)92:3<657::AID-CNCR1367>3.0.CO;2-D;
RA   Beghini A., Tibiletti M.G., Roversi G., Chiaravalli A.M., Serio G.,
RA   Capella C., Larizza L.;
RT   "Germline mutation in the juxtamembrane domain of the kit gene in a
RT   family with gastrointestinal stromal tumors and urticaria
RT   pigmentosa.";
RL   Cancer 92:657-662(2001).
RN   [58]
RP   VARIANT GIST 550-LYS--LYS-558 DEL.
RX   PubMed=15824741; DOI=10.1038/sj.onc.1208587;
RA   Chen L.L., Sabripour M., Wu E.F., Prieto V.G., Fuller G.N.,
RA   Frazier M.L.;
RT   "A mutation-created novel intra-exonic pre-mRNA splice site causes
RT   constitutive activation of KIT in human gastrointestinal stromal
RT   tumors.";
RL   Oncogene 24:4271-4280(2005).
RN   [59]
RP   VARIANTS TYR-816; LYS-822 AND PRO-829.
RX   PubMed=16175573; DOI=10.1002/gcc.20265;
RA   Bignell G., Smith R., Hunter C., Stephens P., Davies H., Greenman C.,
RA   Teague J., Butler A., Edkins S., Stevens C., O'meara S., Parker A.,
RA   Avis T., Barthorpe S., Brackenbury L., Buck G., Clements J., Cole J.,
RA   Dicks E., Edwards K., Forbes S., Gorton M., Gray K., Halliday K.,
RA   Harrison R., Hills K., Hinton J., Jones D., Kosmidou V., Laman R.,
RA   Lugg R., Menzies A., Perry J., Petty R., Raine K., Shepherd R.,
RA   Small A., Solomon H., Stephens Y., Tofts C., Varian J., Webb A.,
RA   West S., Widaa S., Yates A., Gillis A.J.M., Stoop H.J.,
RA   van Gurp R.J.H.L.M., Oosterhuis J.W., Looijenga L.H.J., Futreal P.A.,
RA   Wooster R., Stratton M.R.;
RT   "Sequence analysis of the protein kinase gene family in human
RT   testicular germ-cell tumors of adolescents and adults.";
RL   Genes Chromosomes Cancer 45:42-46(2006).
RN   [60]
RP   VARIANTS [LARGE SCALE ANALYSIS] ILE-532; LEU-541; SER-691; ASN-715;
RP   ASN-737; TRP-804; TYR-816; LYS-822 AND PRO-829.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as cell-surface
CC       receptor for the cytokine KITLG/SCF and plays an essential role in
CC       the regulation of cell survival and proliferation, hematopoiesis,
CC       stem cell maintenance, gametogenesis, mast cell development,
CC       migration and function, and in melanogenesis. In response to
CC       KITLG/SCF binding, KIT can activate several signaling pathways.
CC       Phosphorylates PIK3R1, PLCG1, SH2B2/APS and CBL. Activates the
CC       AKT1 signaling pathway by phosphorylation of PIK3R1, the
CC       regulatory subunit of phosphatidylinositol 3-kinase. Activated KIT
CC       also transmits signals via GRB2 and activation of RAS, RAF1 and
CC       the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. Promotes activation
CC       of STAT family members STAT1, STAT3, STAT5A and STAT5B. Activation
CC       of PLCG1 leads to the production of the cellular signaling
CC       molecules diacylglycerol and inositol 1,4,5-trisphosphate. KIT
CC       signaling is modulated by protein phosphatases, and by rapid
CC       internalization and degradation of the receptor. Activated KIT
CC       promotes phosphorylation of the protein phosphatases PTPN6/SHP-1
CC       and PTPRU, and of the transcription factors STAT1, STAT3, STAT5A
CC       and STAT5B. Promotes phosphorylation of PIK3R1, CBL, CRK (isoform
CC       Crk-II), LYN, MAPK1/ERK2 and/or MAPK3/ERK1, PLCG1, SRC and SHC1.
CC       {ECO:0000269|PubMed:10397721, ECO:0000269|PubMed:12444928,
CC       ECO:0000269|PubMed:12511554, ECO:0000269|PubMed:12878163,
CC       ECO:0000269|PubMed:17904548, ECO:0000269|PubMed:19265199,
CC       ECO:0000269|PubMed:21135090, ECO:0000269|PubMed:21640708,
CC       ECO:0000269|PubMed:7520444, ECO:0000269|PubMed:9528781}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:17662946,
CC       ECO:0000269|PubMed:19164557, ECO:0000269|PubMed:21640708,
CC       ECO:0000269|PubMed:2448137}.
CC   -!- ENZYME REGULATION: Present in an inactive conformation in the
CC       absence of bound ligand. KITLG/SCF binding leads to dimerization
CC       and activation by autophosphorylation on tyrosine residues.
CC       Activity is down-regulated by PRKCA-mediated phosphorylation on
CC       serine residues. Inhibited by imatinib/STI-571 (Gleevec) and
CC       sunitinib; these compounds maintain the kinase in an inactive
CC       conformation. {ECO:0000269|PubMed:15123710,
CC       ECO:0000269|PubMed:19164557, ECO:0000269|PubMed:21640708,
CC       ECO:0000269|PubMed:7520444, ECO:0000269|PubMed:7539802}.
CC   -!- SUBUNIT: Monomer in the absence of bound KITLG/SCF. Homodimer in
CC       the presence of bound KITLG/SCF, forming a heterotetramer with two
CC       KITLG/SCF molecules. Interacts (via phosphorylated tyrosine
CC       residues) with the adapter proteins GRB2 and GRB7 (via SH2
CC       domain), and SH2B2/APS. Interacts (via C-terminus) with MPDZ (via
CC       the tenth PDZ domain). Interacts (via phosphorylated tyrosine
CC       residues) with PIK3R1 and PIK3 catalytic subunit. Interacts (via
CC       phosphorylated tyrosine) with CRK (isoform Crk-II), FYN, SHC1 and
CC       MATK/CHK (via SH2 domain). Interacts with LYN and FES/FPS.
CC       Interacts (via phosphorylated tyrosine residues) with the protein
CC       phosphatases PTPN6/SHP-1 (via SH2 domain), PTPN11/SHP-2 (via SH2
CC       domain) and PTPRU. Interacts with PLCG1. Interacts with DOK1 and
CC       TEC. Interacts (KITLG/SCF-bound) with IL1RL1. Interacts with
CC       IL1RAP (independent of stimulation with KITLG/SCF). A mast cell-
CC       specific KITLG/SCF-induced interleukin-33 signaling complex
CC       contains IL1RL1, IL1RAP, KIT and MYD88.
CC       {ECO:0000250|UniProtKB:P05532, ECO:0000269|PubMed:10377264,
CC       ECO:0000269|PubMed:10397721, ECO:0000269|PubMed:11018522,
CC       ECO:0000269|PubMed:11825908, ECO:0000269|PubMed:12444928,
CC       ECO:0000269|PubMed:12824176, ECO:0000269|PubMed:12878163,
CC       ECO:0000269|PubMed:17595334, ECO:0000269|PubMed:17662946,
CC       ECO:0000269|PubMed:17904548, ECO:0000269|PubMed:19164557,
CC       ECO:0000269|PubMed:21030588, ECO:0000269|PubMed:21640708,
CC       ECO:0000269|PubMed:7520444, ECO:0000269|PubMed:9038210,
CC       ECO:0000269|PubMed:9341198, ECO:0000269|PubMed:9528781}.
CC   -!- INTERACTION:
CC       P00519:ABL1; NbExp=2; IntAct=EBI-1379503, EBI-375543;
CC       P42684:ABL2; NbExp=2; IntAct=EBI-1379503, EBI-1102694;
CC       O75815:BCAR3; NbExp=3; IntAct=EBI-1379503, EBI-702336;
CC       P51451:BLK; NbExp=5; IntAct=EBI-1379503, EBI-2105445;
CC       Q8WV28:BLNK; NbExp=2; IntAct=EBI-1379503, EBI-2623522;
CC       P46108:CRK; NbExp=4; IntAct=EBI-1379503, EBI-886;
CC       P07332:FES; NbExp=2; IntAct=EBI-1379503, EBI-1055635;
CC       P09769:FGR; NbExp=2; IntAct=EBI-1379503, EBI-1383732;
CC       O75791:GRAP2; NbExp=2; IntAct=EBI-1379503, EBI-740418;
CC       P62993:GRB2; NbExp=6; IntAct=EBI-1379503, EBI-401755;
CC       Q14451:GRB7; NbExp=4; IntAct=EBI-1379503, EBI-970191;
CC       P08631:HCK; NbExp=2; IntAct=EBI-1379503, EBI-346340;
CC       Q96JZ2:HSH2D; NbExp=5; IntAct=EBI-1379503, EBI-3919324;
CC       P21583:KITLG; NbExp=2; IntAct=EBI-1379503, EBI-1379527;
CC       P06239:LCK; NbExp=8; IntAct=EBI-1379503, EBI-1348;
CC       P07948:LYN; NbExp=7; IntAct=EBI-1379503, EBI-79452;
CC       Q8VBX6:Mpdz (xeno); NbExp=4; IntAct=EBI-1379503, EBI-8026435;
CC       P16333:NCK1; NbExp=3; IntAct=EBI-1379503, EBI-389883;
CC       O43639:NCK2; NbExp=2; IntAct=EBI-1379503, EBI-713635;
CC       P27986:PIK3R1; NbExp=19; IntAct=EBI-1379503, EBI-79464;
CC       O00459:PIK3R2; NbExp=19; IntAct=EBI-1379503, EBI-346930;
CC       Q92569:PIK3R3; NbExp=31; IntAct=EBI-1379503, EBI-79893;
CC       P19174:PLCG1; NbExp=31; IntAct=EBI-1379503, EBI-79387;
CC       P16885:PLCG2; NbExp=8; IntAct=EBI-1379503, EBI-617403;
CC       Q13882:PTK6; NbExp=4; IntAct=EBI-1379503, EBI-1383632;
CC       Q06124:PTPN11; NbExp=29; IntAct=EBI-1379503, EBI-297779;
CC       P35235:Ptpn11 (xeno); NbExp=2; IntAct=EBI-1379503, EBI-397236;
CC       Q92729:PTPRU; NbExp=2; IntAct=EBI-1379503, EBI-7052301;
CC       P20936:RASA1; NbExp=16; IntAct=EBI-1379503, EBI-1026476;
CC       Q9UQQ2:SH2B3; NbExp=2; IntAct=EBI-1379503, EBI-7879749;
CC       O14796:SH2D1B; NbExp=8; IntAct=EBI-1379503, EBI-3923013;
CC       Q9NP31:SH2D2A; NbExp=10; IntAct=EBI-1379503, EBI-490630;
CC       Q8N5H7:SH2D3C; NbExp=4; IntAct=EBI-1379503, EBI-745980;
CC       P78314:SH3BP2; NbExp=3; IntAct=EBI-1379503, EBI-727062;
CC       Q15464:SHB; NbExp=2; IntAct=EBI-1379503, EBI-4402156;
CC       P29353:SHC1; NbExp=8; IntAct=EBI-1379503, EBI-78835;
CC       P98077:SHC2; NbExp=5; IntAct=EBI-1379503, EBI-7256023;
CC       Q92529:SHC3; NbExp=3; IntAct=EBI-1379503, EBI-79084;
CC       Q9H6Q3:SLA2; NbExp=2; IntAct=EBI-1379503, EBI-1222854;
CC       O14508:SOCS2; NbExp=4; IntAct=EBI-1379503, EBI-617737;
CC       O14543:SOCS3; NbExp=3; IntAct=EBI-1379503, EBI-714146;
CC       O14544:SOCS6; NbExp=12; IntAct=EBI-1379503, EBI-3929549;
CC       P12931:SRC; NbExp=5; IntAct=EBI-1379503, EBI-621482;
CC       Q9ULZ2:STAP1; NbExp=3; IntAct=EBI-1379503, EBI-6083058;
CC       Q9HBL0:TNS1; NbExp=2; IntAct=EBI-1379503, EBI-3389814;
CC       Q63HR2:TNS2; NbExp=2; IntAct=EBI-1379503, EBI-949753;
CC       Q68CZ2:TNS3; NbExp=5; IntAct=EBI-1379503, EBI-1220488;
CC       P42681:TXK; NbExp=3; IntAct=EBI-1379503, EBI-7877438;
CC       P07947:YES1; NbExp=7; IntAct=EBI-1379503, EBI-515331;
CC       P43403:ZAP70; NbExp=2; IntAct=EBI-1379503, EBI-1211276;
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Cell membrane; Single-pass type I
CC       membrane protein.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cell membrane; Single-pass type I
CC       membrane protein.
CC   -!- SUBCELLULAR LOCATION: Isoform 3: Cytoplasm. Note=Detected in the
CC       cytoplasm of spermatozoa, especially in the equatorial and
CC       subacrosomal region of the sperm head.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=GNNK(+), KitA(+);
CC         IsoId=P10721-1; Sequence=Displayed;
CC       Name=2; Synonyms=GNNK(-), Kit(+);
CC         IsoId=P10721-2; Sequence=VSP_038385;
CC       Name=3; Synonyms=TR-KIT;
CC         IsoId=P10721-3; Sequence=VSP_041866, VSP_041867;
CC   -!- TISSUE SPECIFICITY: Isoform 1 and isoform 2 are detected in
CC       spermatogonia and Leydig cells. Isoform 3 is detected in round
CC       spermatids, elongating spermatids and spermatozoa (at protein
CC       level). Widely expressed. Detected in the hematopoietic system,
CC       the gastrointestinal system, in melanocytes and in germ cells.
CC       {ECO:0000269|PubMed:20601678, ECO:0000269|PubMed:2448137}.
CC   -!- INDUCTION: Up-regulated by cis-retinoic acid in neuroblastoma cell
CC       lines. {ECO:0000269|PubMed:20658618}.
CC   -!- PTM: Ubiquitinated by SOCS6. KIT is rapidly ubiquitinated after
CC       autophosphorylation induced by KITLG/SCF binding, leading to
CC       internalization and degradation. {ECO:0000269|PubMed:17904548,
CC       ECO:0000269|PubMed:19265199}.
CC   -!- PTM: Autophosphorylated on tyrosine residues. KITLG/SCF binding
CC       enhances autophosphorylation. Isoform 1 shows low levels of
CC       tyrosine phosphorylation in the absence of added KITLG/SCF (in
CC       vitro). Kinase activity is down-regulated by phosphorylation on
CC       serine residues by protein kinase C family members.
CC       Phosphorylation at Tyr-568 is required for interaction with
CC       PTPN11/SHP-2, CRK (isoform Crk-II) and members of the SRC
CC       tyrosine-protein kinase family. Phosphorylation at Tyr-570 is
CC       required for interaction with PTPN6/SHP-1. Phosphorylation at Tyr-
CC       703, Tyr-823 and Tyr-936 is important for interaction with GRB2.
CC       Phosphorylation at Tyr-721 is important for interaction with
CC       PIK3R1. Phosphorylation at Tyr-823 and Tyr-936 is important for
CC       interaction with GRB7. {ECO:0000269|PubMed:10377264,
CC       ECO:0000269|PubMed:12824176, ECO:0000269|PubMed:19265199,
CC       ECO:0000269|PubMed:20147452, ECO:0000269|PubMed:21030588,
CC       ECO:0000269|PubMed:9038210}.
CC   -!- DISEASE: Piebald trait (PBT) [MIM:172800]: Autosomal dominant
CC       genetic developmental abnormality of pigmentation characterized by
CC       congenital patches of white skin and hair that lack melanocytes.
CC       {ECO:0000269|PubMed:11074500, ECO:0000269|PubMed:1370874,
CC       ECO:0000269|PubMed:1376329, ECO:0000269|PubMed:1717985,
CC       ECO:0000269|PubMed:7687267, ECO:0000269|PubMed:8680409,
CC       ECO:0000269|PubMed:9450866, ECO:0000269|PubMed:9699740}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Gastrointestinal stromal tumor (GIST) [MIM:606764]:
CC       Common mesenchymal neoplasms arising in the gastrointestinal
CC       tract, most often in the stomach. They are histologically,
CC       immunohistochemically, and genetically different from typical
CC       leiomyomas, leiomyosarcomas, and schwannomas. Most GISTs are
CC       composed of a fairly uniform population of spindle-shaped cells.
CC       Some tumors are dominated by epithelioid cells or contain a
CC       mixture of spindle and epithelioid morphologies. Primary GISTs in
CC       the gastrointestinal tract commonly metastasize in the omentum and
CC       mesenteries, often as multiple nodules. However, primary tumors
CC       may also occur outside of the gastrointestinal tract, in other
CC       intra-abdominal locations, especially in the omentum and
CC       mesentery. {ECO:0000269|PubMed:11505412,
CC       ECO:0000269|PubMed:15824741, ECO:0000269|PubMed:9438854,
CC       ECO:0000269|PubMed:9697690}. Note=The gene represented in this
CC       entry is involved in disease pathogenesis.
CC   -!- DISEASE: Testicular germ cell tumor (TGCT) [MIM:273300]: A common
CC       malignancy in males representing 95% of all testicular neoplasms.
CC       TGCTs have various pathologic subtypes including: unclassified
CC       intratubular germ cell neoplasia, seminoma (including cases with
CC       syncytiotrophoblastic cells), spermatocytic seminoma, embryonal
CC       carcinoma, yolk sac tumor, choriocarcinoma, and teratoma. Note=The
CC       gene represented in this entry may be involved in disease
CC       pathogenesis.
CC   -!- DISEASE: Leukemia, acute myelogenous (AML) [MIM:601626]: A subtype
CC       of acute leukemia, a cancer of the white blood cells. AML is a
CC       malignant disease of bone marrow characterized by maturational
CC       arrest of hematopoietic precursors at an early stage of
CC       development. Clonal expansion of myeloid blasts occurs in bone
CC       marrow, blood, and other tissue. Myelogenous leukemias develop
CC       from changes in cells that normally produce neutrophils,
CC       basophils, eosinophils and monocytes. Note=The gene represented in
CC       this entry is involved in disease pathogenesis. Somatic mutations
CC       that lead to constitutive activation of KIT are detected in AML
CC       patients. These mutations fall into two classes, the most common
CC       being in-frame internal tandem duplications of variable length in
CC       the juxtamembrane region that disrupt the normal regulation of the
CC       kinase activity. Likewise, point mutations in the kinase domain
CC       can result in a constitutively activated kinase.
CC   -!- MISCELLANEOUS: Numerous proteins are phosphorylated in response to
CC       KIT signaling, but it is not evident to determine which are
CC       directly phosphorylated by KIT under in vivo conditions.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. CSF-1/PDGF receptor subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/KITID127.html";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=CD117 entry;
CC       URL="https://en.wikipedia.org/wiki/CD117";
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=two's company - Issue
CC       163 of August 2014;
CC       URL="http://web.expasy.org/spotlight/back_issues/163/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X06182; CAA29548.1; -; mRNA.
DR   EMBL; X69301; CAA49159.1; -; Genomic_DNA.
DR   EMBL; X69302; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69303; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69304; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69305; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69306; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69307; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69308; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69309; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69310; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69311; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69312; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69313; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69314; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69315; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; X69316; CAA49159.1; JOINED; Genomic_DNA.
DR   EMBL; U63834; AAC50968.1; -; Genomic_DNA.
DR   EMBL; U63834; AAC50969.1; -; Genomic_DNA.
DR   EMBL; EU826594; ACF47630.1; -; mRNA.
DR   EMBL; GU983671; ADF36702.1; -; mRNA.
DR   EMBL; HM015525; ADF50068.1; -; mRNA.
DR   EMBL; HM015526; ADF50069.1; -; mRNA.
DR   EMBL; AK304031; BAG64945.1; -; mRNA.
DR   EMBL; AC006552; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC092545; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC071593; AAH71593.1; -; mRNA.
DR   EMBL; S67773; AAB29529.1; -; Genomic_DNA.
DR   CCDS; CCDS3496.1; -. [P10721-1]
DR   CCDS; CCDS47058.1; -. [P10721-2]
DR   PIR; S01426; TVHUKT.
DR   RefSeq; NP_000213.1; NM_000222.2. [P10721-1]
DR   RefSeq; NP_001087241.1; NM_001093772.1. [P10721-2]
DR   UniGene; Hs.479754; -.
DR   PDB; 1PKG; X-ray; 2.90 A; A/B=549-935.
DR   PDB; 1QZJ; Model; -; A=576-932.
DR   PDB; 1QZK; Model; -; A=576-932.
DR   PDB; 1R01; Model; -; A=576-932.
DR   PDB; 1T45; X-ray; 1.90 A; A=547-693, A=754-935.
DR   PDB; 1T46; X-ray; 1.60 A; A=565-693, A=754-935.
DR   PDB; 2E9W; X-ray; 3.50 A; A/B=26-514.
DR   PDB; 2EC8; X-ray; 3.00 A; A=1-519.
DR   PDB; 2IUH; X-ray; 2.00 A; B=718-728.
DR   PDB; 2VIF; X-ray; 1.45 A; P=564-574.
DR   PDB; 3G0E; X-ray; 1.60 A; A=544-693, A=754-935.
DR   PDB; 3G0F; X-ray; 2.60 A; A/B=544-693, A/B=754-935.
DR   PDB; 4HVS; X-ray; 1.90 A; A=551-934.
DR   PDB; 4K94; X-ray; 2.40 A; C=308-518.
DR   PDB; 4K9E; X-ray; 2.70 A; C=308-518.
DR   PDB; 4PGZ; X-ray; 2.40 A; A/B/C=308-518.
DR   PDB; 4U0I; X-ray; 2.00 A; A=563-693, A=754-935.
DR   PDBsum; 1PKG; -.
DR   PDBsum; 1QZJ; -.
DR   PDBsum; 1QZK; -.
DR   PDBsum; 1R01; -.
DR   PDBsum; 1T45; -.
DR   PDBsum; 1T46; -.
DR   PDBsum; 2E9W; -.
DR   PDBsum; 2EC8; -.
DR   PDBsum; 2IUH; -.
DR   PDBsum; 2VIF; -.
DR   PDBsum; 3G0E; -.
DR   PDBsum; 3G0F; -.
DR   PDBsum; 4HVS; -.
DR   PDBsum; 4K94; -.
DR   PDBsum; 4K9E; -.
DR   PDBsum; 4PGZ; -.
DR   PDBsum; 4U0I; -.
DR   ProteinModelPortal; P10721; -.
DR   SMR; P10721; -.
DR   BioGrid; 110015; 43.
DR   DIP; DIP-1055N; -.
DR   IntAct; P10721; 65.
DR   MINT; MINT-146746; -.
DR   STRING; 9606.ENSP00000288135; -.
DR   BindingDB; P10721; -.
DR   ChEMBL; CHEMBL1936; -.
DR   DrugBank; DB06080; ABT-869.
DR   DrugBank; DB01254; Dasatinib.
DR   DrugBank; DB00619; Imatinib.
DR   DrugBank; DB09078; Lenvatinib.
DR   DrugBank; DB05216; MP470.
DR   DrugBank; DB04868; Nilotinib.
DR   DrugBank; DB05913; OSI-930.
DR   DrugBank; DB06589; Pazopanib.
DR   DrugBank; DB01962; Phosphonotyrosine.
DR   DrugBank; DB08901; Ponatinib.
DR   DrugBank; DB08896; Regorafenib.
DR   DrugBank; DB00398; Sorafenib.
DR   DrugBank; DB01268; Sunitinib.
DR   DrugBank; DB05153; XL184.
DR   DrugBank; DB05146; XL820.
DR   GuidetoPHARMACOLOGY; 1805; -.
DR   iPTMnet; P10721; -.
DR   PhosphoSitePlus; P10721; -.
DR   BioMuta; KIT; -.
DR   DMDM; 125472; -.
DR   MaxQB; P10721; -.
DR   PaxDb; P10721; -.
DR   PeptideAtlas; P10721; -.
DR   PRIDE; P10721; -.
DR   DNASU; 3815; -.
DR   Ensembl; ENST00000288135; ENSP00000288135; ENSG00000157404. [P10721-1]
DR   Ensembl; ENST00000412167; ENSP00000390987; ENSG00000157404. [P10721-2]
DR   GeneID; 3815; -.
DR   KEGG; hsa:3815; -.
DR   UCSC; uc010igr.4; human. [P10721-1]
DR   CTD; 3815; -.
DR   DisGeNET; 3815; -.
DR   GeneCards; KIT; -.
DR   HGNC; HGNC:6342; KIT.
DR   HPA; CAB003288; -.
DR   HPA; CAB068253; -.
DR   HPA; CAB072867; -.
DR   HPA; HPA004471; -.
DR   HPA; HPA073252; -.
DR   MalaCards; KIT; -.
DR   MIM; 164920; gene.
DR   MIM; 172800; phenotype.
DR   MIM; 273300; phenotype.
DR   MIM; 601626; phenotype.
DR   MIM; 606764; phenotype.
DR   neXtProt; NX_P10721; -.
DR   OpenTargets; ENSG00000157404; -.
DR   Orphanet; 98829; 'Acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)'.
DR   Orphanet; 102724; 'Acute myeloid leukemia with t(8;21)(q22;q22) translocation'.
DR   Orphanet; 98834; Acute myeloblastic leukemia with maturation.
DR   Orphanet; 158799; Aleukemic mast cell leukemia.
DR   Orphanet; 280785; Bullous diffuse cutaneous mastocytosis.
DR   Orphanet; 158796; Classic mast cell leukemia.
DR   Orphanet; 79455; Cutaneous mastocytoma.
DR   Orphanet; 44890; Gastrointestinal stromal tumor.
DR   Orphanet; 158778; Isolated bone marrow mastocytosis.
DR   Orphanet; 158793; Lymphoadenopathic mastocytosis with eosinophilia.
DR   Orphanet; 158772; Nodular urticaria pigmentosa.
DR   Orphanet; 2884; Piebaldism.
DR   Orphanet; 158769; Plaque-form urticaria pigmentosa.
DR   Orphanet; 280794; Pseudoxanthomatous diffuse cutaneous mastocytosis.
DR   Orphanet; 158775; Smouldering systemic mastocytosis.
DR   Orphanet; 98849; Systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disease.
DR   Orphanet; 90389; Telangiectasia macularis eruptiva perstans.
DR   Orphanet; 158766; Typical urticaria pigmentosa.
DR   PharmGKB; PA30128; -.
DR   eggNOG; KOG0200; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118923; -.
DR   HOGENOM; HOG000112008; -.
DR   HOVERGEN; HBG104348; -.
DR   InParanoid; P10721; -.
DR   KO; K05091; -.
DR   OMA; YFCPGTE; -.
DR   OrthoDB; EOG091G01TL; -.
DR   PhylomeDB; P10721; -.
DR   TreeFam; TF325768; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-1433557; Signaling by SCF-KIT.
DR   Reactome; R-HSA-1433559; Regulation of KIT signaling.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-8866910; TFAP2 (AP-2) family regulates transcription of growth factors and their receptors.
DR   SignaLink; P10721; -.
DR   SIGNOR; P10721; -.
DR   ChiTaRS; KIT; human.
DR   EvolutionaryTrace; P10721; -.
DR   GeneWiki; CD117; -.
DR   GenomeRNAi; 3815; -.
DR   PRO; PR:P10721; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; ENSG00000157404; -.
DR   CleanEx; HS_KIT; -.
DR   ExpressionAtlas; P10721; baseline and differential.
DR   Genevisible; P10721; HS.
DR   GO; GO:0001669; C:acrosomal vesicle; IEA:Ensembl.
DR   GO; GO:0005911; C:cell-cell junction; IEA:Ensembl.
DR   GO; GO:0009898; C:cytoplasmic side of plasma membrane; IEA:Ensembl.
DR   GO; GO:0009897; C:external side of plasma membrane; IEA:Ensembl.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0042629; C:mast cell granule; IEA:GOC.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019955; F:cytokine binding; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0046934; F:phosphatidylinositol-4,5-bisphosphate 3-kinase activity; TAS:Reactome.
DR   GO; GO:0002020; F:protease binding; IEA:Ensembl.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; TAS:ProtInc.
DR   GO; GO:0005088; F:Ras guanyl-nucleotide exchange factor activity; TAS:Reactome.
DR   GO; GO:0004716; F:signal transducer, downstream of receptor, with protein tyrosine kinase activity; TAS:ProtInc.
DR   GO; GO:0005020; F:stem cell factor receptor activity; IEA:Ensembl.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0031532; P:actin cytoskeleton reorganization; IDA:UniProtKB.
DR   GO; GO:0000187; P:activation of MAPK activity; IDA:UniProtKB.
DR   GO; GO:0060326; P:cell chemotaxis; IDA:UniProtKB.
DR   GO; GO:0097067; P:cellular response to thyroid hormone stimulus; IEA:Ensembl.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0002371; P:dendritic cell cytokine production; ISS:UniProtKB.
DR   GO; GO:0050910; P:detection of mechanical stimulus involved in sensory perception of sound; ISS:UniProtKB.
DR   GO; GO:0048565; P:digestive tract development; ISS:UniProtKB.
DR   GO; GO:0035234; P:ectopic germ cell programmed cell death; IEA:Ensembl.
DR   GO; GO:0035162; P:embryonic hemopoiesis; ISS:UniProtKB.
DR   GO; GO:0050673; P:epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0030218; P:erythrocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0038162; P:erythropoietin-mediated signaling pathway; ISS:UniProtKB.
DR   GO; GO:0038093; P:Fc receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0008354; P:germ cell migration; IEA:Ensembl.
DR   GO; GO:0006687; P:glycosphingolipid metabolic process; IEA:Ensembl.
DR   GO; GO:0035701; P:hematopoietic stem cell migration; IEA:Ensembl.
DR   GO; GO:0030097; P:hemopoiesis; TAS:UniProtKB.
DR   GO; GO:0002327; P:immature B cell differentiation; ISS:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; ISS:UniProtKB.
DR   GO; GO:0038109; P:Kit signaling pathway; IDA:UniProtKB.
DR   GO; GO:0030032; P:lamellipodium assembly; ISS:UniProtKB.
DR   GO; GO:0002320; P:lymphoid progenitor cell differentiation; IEA:Ensembl.
DR   GO; GO:0008584; P:male gonad development; IEP:UniProtKB.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0002551; P:mast cell chemotaxis; IDA:UniProtKB.
DR   GO; GO:0032762; P:mast cell cytokine production; IDA:UniProtKB.
DR   GO; GO:0043303; P:mast cell degranulation; IMP:UniProtKB.
DR   GO; GO:0060374; P:mast cell differentiation; ISS:UniProtKB.
DR   GO; GO:0070662; P:mast cell proliferation; TAS:UniProtKB.
DR   GO; GO:0035855; P:megakaryocyte development; ISS:UniProtKB.
DR   GO; GO:0097326; P:melanocyte adhesion; ISS:UniProtKB.
DR   GO; GO:0030318; P:melanocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0097324; P:melanocyte migration; ISS:UniProtKB.
DR   GO; GO:0002318; P:myeloid progenitor cell differentiation; IEA:Ensembl.
DR   GO; GO:0043069; P:negative regulation of programmed cell death; IEA:Ensembl.
DR   GO; GO:0001541; P:ovarian follicle development; ISS:UniProtKB.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:Reactome.
DR   GO; GO:0043473; P:pigmentation; ISS:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IEA:Ensembl.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0046427; P:positive regulation of JAK-STAT cascade; IMP:UniProtKB.
DR   GO; GO:0048170; P:positive regulation of long-term neuronal synaptic plasticity; IEA:Ensembl.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IMP:UniProtKB.
DR   GO; GO:0045747; P:positive regulation of Notch signaling pathway; IEA:Ensembl.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; TAS:UniProtKB.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; TAS:UniProtKB.
DR   GO; GO:0010863; P:positive regulation of phospholipase C activity; TAS:UniProtKB.
DR   GO; GO:0031274; P:positive regulation of pseudopodium assembly; IEA:Ensembl.
DR   GO; GO:0051091; P:positive regulation of sequence-specific DNA binding transcription factor activity; IMP:UniProtKB.
DR   GO; GO:0042511; P:positive regulation of tyrosine phosphorylation of Stat1 protein; IMP:UniProtKB.
DR   GO; GO:0042517; P:positive regulation of tyrosine phosphorylation of Stat3 protein; IMP:UniProtKB.
DR   GO; GO:0042523; P:positive regulation of tyrosine phosphorylation of Stat5 protein; IMP:UniProtKB.
DR   GO; GO:1905065; P:positive regulation of vascular smooth muscle cell differentiation; IDA:BHF-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0042127; P:regulation of cell proliferation; TAS:UniProtKB.
DR   GO; GO:0008360; P:regulation of cell shape; ISS:UniProtKB.
DR   GO; GO:0048070; P:regulation of developmental pigmentation; IEA:Ensembl.
DR   GO; GO:0014066; P:regulation of phosphatidylinositol 3-kinase signaling; TAS:Reactome.
DR   GO; GO:0006357; P:regulation of transcription from RNA polymerase II promoter; TAS:Reactome.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0048103; P:somatic stem cell division; IEA:Ensembl.
DR   GO; GO:0035019; P:somatic stem cell population maintenance; IEA:Ensembl.
DR   GO; GO:0007286; P:spermatid development; IEA:Ensembl.
DR   GO; GO:0007283; P:spermatogenesis; ISS:UniProtKB.
DR   GO; GO:0048863; P:stem cell differentiation; ISS:UniProtKB.
DR   GO; GO:0019827; P:stem cell population maintenance; TAS:UniProtKB.
DR   GO; GO:0030217; P:T cell differentiation; ISS:UniProtKB.
DR   GO; GO:0008542; P:visual learning; IEA:Ensembl.
DR   Gene3D; 2.60.40.10; -; 5.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR013151; Immunoglobulin.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR027263; SCGF_receptor.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016243; Tyr_kinase_CSF1/PDGF_rcpt.
DR   InterPro; IPR001824; Tyr_kinase_rcpt_3_CS.
DR   Pfam; PF00047; ig; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PIRSF; PIRSF500951; SCGF_recepter; 1.
DR   PIRSF; PIRSF000615; TyrPK_CSF1-R; 1.
DR   SMART; SM00409; IG; 3.
DR   SMART; SM00408; IGc2; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 3.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00240; RECEPTOR_TYR_KIN_III; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Complete proteome; Cytoplasm; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; Glycoprotein; Immunoglobulin domain;
KW   Kinase; Magnesium; Membrane; Metal-binding; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Proto-oncogene; Receptor;
KW   Reference proteome; Repeat; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     25       {ECO:0000255}.
FT   CHAIN        26    976       Mast/stem cell growth factor receptor
FT                                Kit.
FT                                /FTId=PRO_0000016754.
FT   TOPO_DOM     26    524       Extracellular. {ECO:0000255}.
FT   TRANSMEM    525    545       Helical. {ECO:0000255}.
FT   TOPO_DOM    546    976       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       27    112       Ig-like C2-type 1.
FT   DOMAIN      121    205       Ig-like C2-type 2.
FT   DOMAIN      212    308       Ig-like C2-type 3.
FT   DOMAIN      317    410       Ig-like C2-type 4.
FT   DOMAIN      413    507       Ig-like C2-type 5.
FT   DOMAIN      589    937       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     596    603       ATP.
FT   NP_BIND     671    677       ATP.
FT   REGION      568    570       Important for interaction with
FT                                phosphotyrosine-binding proteins.
FT   ACT_SITE    792    792       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   METAL       568    568       Magnesium.
FT   METAL       797    797       Magnesium.
FT   METAL       810    810       Magnesium.
FT   BINDING     623    623       ATP.
FT   BINDING     796    796       ATP.
FT   SITE        936    936       Important for interaction with
FT                                phosphotyrosine-binding proteins.
FT   MOD_RES     547    547       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000305|PubMed:20147452}.
FT   MOD_RES     553    553       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000305|PubMed:20147452}.
FT   MOD_RES     568    568       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12824176,
FT                                ECO:0000269|PubMed:19265199,
FT                                ECO:0000269|PubMed:21030588,
FT                                ECO:0000269|PubMed:9038210}.
FT   MOD_RES     570    570       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12824176,
FT                                ECO:0000269|PubMed:9038210}.
FT   MOD_RES     703    703       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:10377264,
FT                                ECO:0000269|PubMed:19265199,
FT                                ECO:0000269|PubMed:20147452}.
FT   MOD_RES     721    721       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:19265199,
FT                                ECO:0000269|PubMed:20147452,
FT                                ECO:0000269|PubMed:9038210}.
FT   MOD_RES     730    730       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000305|PubMed:20147452}.
FT   MOD_RES     741    741       Phosphoserine; by PKC/PRKCA.
FT                                {ECO:0000269|PubMed:7539802}.
FT   MOD_RES     746    746       Phosphoserine; by PKC/PRKCA.
FT                                {ECO:0000269|PubMed:7539802}.
FT   MOD_RES     821    821       Phosphoserine.
FT                                {ECO:0000269|PubMed:7539802}.
FT   MOD_RES     823    823       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:20147452}.
FT   MOD_RES     891    891       Phosphoserine.
FT                                {ECO:0000269|PubMed:12878163}.
FT   MOD_RES     900    900       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12878163,
FT                                ECO:0000269|PubMed:20147452}.
FT   MOD_RES     936    936       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:10377264,
FT                                ECO:0000269|PubMed:19265199}.
FT   MOD_RES     959    959       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195,
FT                                ECO:0000269|PubMed:7539802}.
FT   CARBOHYD    130    130       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:17662946}.
FT   CARBOHYD    145    145       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    283    283       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:17662946}.
FT   CARBOHYD    293    293       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:17662946}.
FT   CARBOHYD    300    300       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:17662946}.
FT   CARBOHYD    320    320       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:17662946}.
FT   CARBOHYD    352    352       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:17662946}.
FT   CARBOHYD    367    367       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:17662946}.
FT   CARBOHYD    463    463       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    486    486       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     58     97       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:17662946}.
FT   DISULFID    136    186       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:17662946}.
FT   DISULFID    151    183       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:17662946}.
FT   DISULFID    233    290       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:17662946}.
FT   DISULFID    428    491       {ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:17662946}.
FT   VAR_SEQ     412    413       KP -> SL (in isoform 3).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_041866.
FT   VAR_SEQ     414    976       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_041867.
FT   VAR_SEQ     510    513       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:20658618,
FT                                ECO:0000303|Ref.6}.
FT                                /FTId=VSP_038385.
FT   VARIANT     532    532       V -> I (in dbSNP:rs55792975).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042021.
FT   VARIANT     541    541       M -> L (in dbSNP:rs3822214).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042022.
FT   VARIANT     541    541       M -> V (in dbSNP:rs3822214).
FT                                /FTId=VAR_061289.
FT   VARIANT     550    558       Missing (in GIST; somatic mutation).
FT                                {ECO:0000269|PubMed:15824741,
FT                                ECO:0000269|PubMed:9438854}.
FT                                /FTId=VAR_033124.
FT   VARIANT     550    550       K -> I (in GIST; somatic mutation;
FT                                dbSNP:rs28933968).
FT                                {ECO:0000269|PubMed:9438854}.
FT                                /FTId=VAR_033123.
FT   VARIANT     551    555       Missing (in GIST; somatic mutation).
FT                                {ECO:0000269|PubMed:9438854}.
FT                                /FTId=VAR_033125.
FT   VARIANT     559    560       Missing (in GIST; somatic mutation).
FT                                {ECO:0000269|PubMed:9438854}.
FT                                /FTId=VAR_033128.
FT   VARIANT     559    559       V -> A (in GIST; dbSNP:rs121913517).
FT                                {ECO:0000269|PubMed:11505412}.
FT                                /FTId=VAR_033126.
FT   VARIANT     559    559       V -> D (in GIST; somatic mutation;
FT                                dbSNP:rs121913517).
FT                                {ECO:0000269|PubMed:9438854}.
FT                                /FTId=VAR_033127.
FT   VARIANT     559    559       Missing (in GIST).
FT                                {ECO:0000269|PubMed:9697690}.
FT                                /FTId=VAR_007965.
FT   VARIANT     583    583       E -> K (in PBT; dbSNP:rs121913680).
FT                                {ECO:0000269|PubMed:1376329}.
FT                                /FTId=VAR_004104.
FT   VARIANT     584    584       F -> C (in PBT; dbSNP:rs28933371).
FT                                {ECO:0000269|PubMed:11074500}.
FT                                /FTId=VAR_033129.
FT   VARIANT     584    584       F -> L (in PBT; dbSNP:rs794726671).
FT                                {ECO:0000269|PubMed:1370874}.
FT                                /FTId=VAR_004105.
FT   VARIANT     601    601       G -> R (in PBT).
FT                                {ECO:0000269|PubMed:11074500}.
FT                                /FTId=VAR_033130.
FT   VARIANT     656    656       L -> P (in PBT).
FT                                {ECO:0000269|PubMed:11074500}.
FT                                /FTId=VAR_033131.
FT   VARIANT     664    664       G -> R (in PBT; dbSNP:rs121913679).
FT                                {ECO:0000269|PubMed:1717985}.
FT                                /FTId=VAR_004106.
FT   VARIANT     691    691       C -> S (in dbSNP:rs35200131).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042023.
FT   VARIANT     715    715       S -> N (in dbSNP:rs56094246).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042024.
FT   VARIANT     737    737       D -> N (in a colorectal adenocarcinoma
FT                                sample; somatic mutation;
FT                                dbSNP:rs751005114).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042025.
FT   VARIANT     791    791       R -> G (in PBT).
FT                                {ECO:0000269|PubMed:7687267}.
FT                                /FTId=VAR_004107.
FT   VARIANT     796    796       R -> G (in PBT; with sensorineural
FT                                deafness; dbSNP:rs121913684).
FT                                {ECO:0000269|PubMed:9450866}.
FT                                /FTId=VAR_033132.
FT   VARIANT     804    804       R -> W (in a colorectal adenocarcinoma
FT                                sample; somatic mutation;
FT                                dbSNP:rs145602440).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042026.
FT   VARIANT     812    812       G -> V (in PBT).
FT                                {ECO:0000269|PubMed:7687267}.
FT                                /FTId=VAR_004108.
FT   VARIANT     816    816       D -> F (in mastocytosis; requires 2
FT                                nucleotide substitutions; somatic
FT                                mutation; constitutively activated and is
FT                                much more rapidly autophosphorylated than
FT                                wild type). {ECO:0000269|PubMed:9990072}.
FT                                /FTId=VAR_033133.
FT   VARIANT     816    816       D -> H (in a testicular tumor; seminoma;
FT                                somatic mutation; constitutively
FT                                activated; dbSNP:rs28933969).
FT                                {ECO:0000269|PubMed:10362788,
FT                                ECO:0000269|PubMed:19164557,
FT                                ECO:0000269|PubMed:20147452}.
FT                                /FTId=VAR_033134.
FT   VARIANT     816    816       D -> V (in mast cell leukemia and
FT                                mastocytosis; somatic mutation;
FT                                constitutively activated; loss of
FT                                interaction with MPDZ;
FT                                dbSNP:rs121913507).
FT                                {ECO:0000269|PubMed:11018522,
FT                                ECO:0000269|PubMed:17595334,
FT                                ECO:0000269|PubMed:19164557,
FT                                ECO:0000269|PubMed:19265199,
FT                                ECO:0000269|PubMed:21640708,
FT                                ECO:0000269|PubMed:7691885,
FT                                ECO:0000269|PubMed:9990072}.
FT                                /FTId=VAR_004109.
FT   VARIANT     816    816       D -> Y (in acute myeloid leukemia,
FT                                mastocytosis and a germ cell tumor of the
FT                                testis; somatic mutation; constitutively
FT                                activated; dbSNP:rs121913506).
FT                                {ECO:0000269|PubMed:16175573,
FT                                ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:9657776,
FT                                ECO:0000269|PubMed:9990072}.
FT                                /FTId=VAR_023828.
FT   VARIANT     820    820       D -> G (in mast cell disease; systemic;
FT                                dbSNP:rs121913682).
FT                                {ECO:0000269|PubMed:9029028}.
FT                                /FTId=VAR_033135.
FT   VARIANT     822    822       N -> K (in a germ cell tumor of the
FT                                testis; somatic mutation;
FT                                dbSNP:rs121913514).
FT                                {ECO:0000269|PubMed:16175573,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_023829.
FT   VARIANT     829    829       A -> P (in a germ cell tumor of the
FT                                testis; somatic mutation).
FT                                {ECO:0000269|PubMed:16175573,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_023830.
FT   VARIANT     839    839       E -> K (in mastocytosis; somatic
FT                                mutation; dominant negative mutation;
FT                                loss of autophosphorylation;
FT                                dbSNP:rs121913509).
FT                                {ECO:0000269|PubMed:9990072}.
FT                                /FTId=VAR_033136.
FT   VARIANT     847    847       T -> P (in PBT; dbSNP:rs121913687).
FT                                {ECO:0000269|PubMed:9699740}.
FT                                /FTId=VAR_033137.
FT   VARIANT     893    896       Missing (in PBT; severe).
FT                                {ECO:0000269|PubMed:8680409}.
FT                                /FTId=VAR_004110.
FT   MUTAGEN     381    381       R->A: Reduces autophosphorylation in
FT                                response to KITLG/SCF.
FT                                {ECO:0000269|PubMed:17662946}.
FT   MUTAGEN     386    386       E->A: Reduces autophosphorylation in
FT                                response to KITLG/SCF.
FT                                {ECO:0000269|PubMed:17662946}.
FT   MUTAGEN     571    571       I->A: Reduction in SH2B2/APS binding.
FT                                Abolishes SH2B2/APS binding; when
FT                                associated with A-939.
FT                                {ECO:0000269|PubMed:12444928}.
FT   MUTAGEN     623    623       K->M: Stronger interaction with MPDZ.
FT                                {ECO:0000269|PubMed:11018522}.
FT   MUTAGEN     741    741       S->A: Abolishes down-regulation of kinase
FT                                activity by PKC/PRKCA-mediated
FT                                phosphorylation; when associated with A-
FT                                746. {ECO:0000269|PubMed:7539802}.
FT   MUTAGEN     746    746       S->A: Abolishes down-regulation of kinase
FT                                activity by PKC/PRKCA-mediated
FT                                phosphorylation; when associated with A-
FT                                741. {ECO:0000269|PubMed:7539802}.
FT   MUTAGEN     823    823       Y->F: No decrease in activity. Leads to
FT                                autophosphorylation at Tyr-900.
FT                                {ECO:0000269|PubMed:20147452}.
FT   MUTAGEN     939    939       L->A: Reduction in SH2B2/APS binding.
FT                                Abolishes SH2B2/APS binding; when
FT                                associated with A-571.
FT                                {ECO:0000269|PubMed:12444928}.
FT   CONFLICT    764    764       L -> I (in Ref. 9; AAH71593).
FT                                {ECO:0000305}.
FT   CONFLICT    838    838       P -> H (in Ref. 9; AAH71593).
FT                                {ECO:0000305}.
FT   STRAND       38     41       {ECO:0000244|PDB:2EC8}.
FT   STRAND       44     47       {ECO:0000244|PDB:2EC8}.
FT   STRAND       54     59       {ECO:0000244|PDB:2EC8}.
FT   STRAND       63     72       {ECO:0000244|PDB:2EC8}.
FT   STRAND       75     77       {ECO:0000244|PDB:2EC8}.
FT   STRAND       79     86       {ECO:0000244|PDB:2EC8}.
FT   HELIX        89     91       {ECO:0000244|PDB:2E9W}.
FT   STRAND       93     99       {ECO:0000244|PDB:2EC8}.
FT   STRAND      104    110       {ECO:0000244|PDB:2EC8}.
FT   STRAND      125    130       {ECO:0000244|PDB:2E9W}.
FT   STRAND      132    134       {ECO:0000244|PDB:2EC8}.
FT   STRAND      146    149       {ECO:0000244|PDB:2EC8}.
FT   STRAND      151    153       {ECO:0000244|PDB:2EC8}.
FT   STRAND      161    165       {ECO:0000244|PDB:2EC8}.
FT   TURN        166    168       {ECO:0000244|PDB:2EC8}.
FT   STRAND      169    174       {ECO:0000244|PDB:2EC8}.
FT   HELIX       177    179       {ECO:0000244|PDB:2EC8}.
FT   STRAND      183    188       {ECO:0000244|PDB:2EC8}.
FT   STRAND      193    200       {ECO:0000244|PDB:2E9W}.
FT   STRAND      203    205       {ECO:0000244|PDB:2E9W}.
FT   STRAND      213    215       {ECO:0000244|PDB:2EC8}.
FT   STRAND      219    224       {ECO:0000244|PDB:2EC8}.
FT   STRAND      229    239       {ECO:0000244|PDB:2EC8}.
FT   STRAND      243    248       {ECO:0000244|PDB:2EC8}.
FT   STRAND      258    263       {ECO:0000244|PDB:2EC8}.
FT   STRAND      265    267       {ECO:0000244|PDB:2EC8}.
FT   STRAND      269    279       {ECO:0000244|PDB:2EC8}.
FT   TURN        282    284       {ECO:0000244|PDB:2EC8}.
FT   STRAND      286    293       {ECO:0000244|PDB:2EC8}.
FT   STRAND      298    310       {ECO:0000244|PDB:2EC8}.
FT   STRAND      312    319       {ECO:0000244|PDB:4K94}.
FT   STRAND      321    325       {ECO:0000244|PDB:4K94}.
FT   STRAND      331    341       {ECO:0000244|PDB:4K94}.
FT   STRAND      344    350       {ECO:0000244|PDB:4K94}.
FT   STRAND      356    364       {ECO:0000244|PDB:4K94}.
FT   STRAND      367    369       {ECO:0000244|PDB:2EC8}.
FT   STRAND      372    379       {ECO:0000244|PDB:4K94}.
FT   HELIX       384    386       {ECO:0000244|PDB:4K94}.
FT   STRAND      388    395       {ECO:0000244|PDB:4K94}.
FT   STRAND      400    409       {ECO:0000244|PDB:4K94}.
FT   STRAND      411    420       {ECO:0000244|PDB:4K94}.
FT   HELIX       422    424       {ECO:0000244|PDB:4K94}.
FT   STRAND      425    434       {ECO:0000244|PDB:4K94}.
FT   STRAND      437    444       {ECO:0000244|PDB:4K94}.
FT   STRAND      445    449       {ECO:0000244|PDB:4PGZ}.
FT   STRAND      452    454       {ECO:0000244|PDB:4PGZ}.
FT   STRAND      458    462       {ECO:0000244|PDB:4K94}.
FT   STRAND      465    468       {ECO:0000244|PDB:4PGZ}.
FT   STRAND      472    479       {ECO:0000244|PDB:4K94}.
FT   HELIX       481    483       {ECO:0000244|PDB:4PGZ}.
FT   STRAND      485    494       {ECO:0000244|PDB:4K94}.
FT   STRAND      499    506       {ECO:0000244|PDB:4K94}.
FT   STRAND      558    564       {ECO:0000244|PDB:3G0E}.
FT   STRAND      567    570       {ECO:0000244|PDB:3G0E}.
FT   TURN        573    575       {ECO:0000244|PDB:1T46}.
FT   HELIX       580    582       {ECO:0000244|PDB:1T46}.
FT   HELIX       586    588       {ECO:0000244|PDB:1T46}.
FT   STRAND      589    597       {ECO:0000244|PDB:1T46}.
FT   STRAND      599    613       {ECO:0000244|PDB:1T46}.
FT   STRAND      617    625       {ECO:0000244|PDB:1T46}.
FT   HELIX       631    647       {ECO:0000244|PDB:1T46}.
FT   STRAND      656    660       {ECO:0000244|PDB:1T46}.
FT   STRAND      662    665       {ECO:0000244|PDB:1T46}.
FT   STRAND      667    671       {ECO:0000244|PDB:1T46}.
FT   HELIX       678    684       {ECO:0000244|PDB:1T46}.
FT   TURN        685    688       {ECO:0000244|PDB:1T46}.
FT   STRAND      719    721       {ECO:0000244|PDB:2IUH}.
FT   STRAND      757    759       {ECO:0000244|PDB:4HVS}.
FT   HELIX       760    762       {ECO:0000244|PDB:4HVS}.
FT   HELIX       766    785       {ECO:0000244|PDB:1T46}.
FT   STRAND      788    790       {ECO:0000244|PDB:3G0F}.
FT   HELIX       795    797       {ECO:0000244|PDB:1T46}.
FT   STRAND      798    801       {ECO:0000244|PDB:1T46}.
FT   TURN        802    804       {ECO:0000244|PDB:1T46}.
FT   STRAND      805    808       {ECO:0000244|PDB:1T46}.
FT   HELIX       812    814       {ECO:0000244|PDB:1T46}.
FT   HELIX       817    819       {ECO:0000244|PDB:3G0E}.
FT   STRAND      823    825       {ECO:0000244|PDB:1T46}.
FT   STRAND      827    831       {ECO:0000244|PDB:1T46}.
FT   HELIX       833    835       {ECO:0000244|PDB:1T46}.
FT   HELIX       838    843       {ECO:0000244|PDB:1T46}.
FT   HELIX       848    863       {ECO:0000244|PDB:1T46}.
FT   TURN        864    866       {ECO:0000244|PDB:1T46}.
FT   HELIX       877    885       {ECO:0000244|PDB:1T46}.
FT   HELIX       897    906       {ECO:0000244|PDB:1T46}.
FT   HELIX       911    913       {ECO:0000244|PDB:1T46}.
FT   HELIX       917    930       {ECO:0000244|PDB:1T46}.
FT   TURN        931    933       {ECO:0000244|PDB:1T45}.
SQ   SEQUENCE   976 AA;  109865 MW;  81B0CD76817F3454 CRC64;
     MRGARGAWDF LCVLLLLLRV QTGSSQPSVS PGEPSPPSIH PGKSDLIVRV GDEIRLLCTD
     PGFVKWTFEI LDETNENKQN EWITEKAEAT NTGKYTCTNK HGLSNSIYVF VRDPAKLFLV
     DRSLYGKEDN DTLVRCPLTD PEVTNYSLKG CQGKPLPKDL RFIPDPKAGI MIKSVKRAYH
     RLCLHCSVDQ EGKSVLSEKF ILKVRPAFKA VPVVSVSKAS YLLREGEEFT VTCTIKDVSS
     SVYSTWKREN SQTKLQEKYN SWHHGDFNYE RQATLTISSA RVNDSGVFMC YANNTFGSAN
     VTTTLEVVDK GFINIFPMIN TTVFVNDGEN VDLIVEYEAF PKPEHQQWIY MNRTFTDKWE
     DYPKSENESN IRYVSELHLT RLKGTEGGTY TFLVSNSDVN AAIAFNVYVN TKPEILTYDR
     LVNGMLQCVA AGFPEPTIDW YFCPGTEQRC SASVLPVDVQ TLNSSGPPFG KLVVQSSIDS
     SAFKHNGTVE CKAYNDVGKT SAYFNFAFKG NNKEQIHPHT LFTPLLIGFV IVAGMMCIIV
     MILTYKYLQK PMYEVQWKVV EEINGNNYVY IDPTQLPYDH KWEFPRNRLS FGKTLGAGAF
     GKVVEATAYG LIKSDAAMTV AVKMLKPSAH LTEREALMSE LKVLSYLGNH MNIVNLLGAC
     TIGGPTLVIT EYCCYGDLLN FLRRKRDSFI CSKQEDHAEA ALYKNLLHSK ESSCSDSTNE
     YMDMKPGVSY VVPTKADKRR SVRIGSYIER DVTPAIMEDD ELALDLEDLL SFSYQVAKGM
     AFLASKNCIH RDLAARNILL THGRITKICD FGLARDIKND SNYVVKGNAR LPVKWMAPES
     IFNCVYTFES DVWSYGIFLW ELFSLGSSPY PGMPVDSKFY KMIKEGFRML SPEHAPAEMY
     DIMKTCWDAD PLKRPTFKQI VQLIEKQISE STNHIYSNLA NCSPNRQKPV VDHSVRINSV
     GSTASSSQPL LVHDDV
//
